Browse > Article
http://dx.doi.org/10.7314/APJCP.2012.13.11.5353

Immunotherapeutic Approach for Better Management of Cancer - Role of IL-18  

Kuppala, Manohar Babu (Institute of Genetics and Hospital for Genetic Diseases, Osmania University)
Syed, Sunayana Begum (Institute of Genetics and Hospital for Genetic Diseases, Osmania University)
Bandaru, Srinivas (Institute of Genetics and Hospital for Genetic Diseases, Osmania University)
Varre, Sreedevi (Institute of Genetics and Hospital for Genetic Diseases, Osmania University)
Akka, Jyothy (Institute of Genetics and Hospital for Genetic Diseases, Osmania University)
Mundulru, Hema Prasad (Institute of Genetics and Hospital for Genetic Diseases, Osmania University)
Publication Information
Asian Pacific Journal of Cancer Prevention / v.13, no.11, 2012 , pp. 5353-5361 More about this Journal
Abstract
Interleukin-18 (IL-18) is an immune-stimulatory cytokine with antitumor activity in preclinical models. It plays pivotal roles in linking inflammatory immune responses and tumor progression and is a useful candidate in gene therapy of lymphoma or lymphoid leukemia. A phase I study of recombinant human IL-18 (rhIL-18) in patients with advanced cancer concluded that rhIL-18 can be safely given in biologically active doses to patients with advanced cancer. Some viruses can induce the secretion of IL-18 for immune evasion. The individual cytokine activity might be potentiated or inhibited by combinations of cytokines. Here we focus on combinational effects of cytokines with IL-18 in cancer progression. IL-18 is an important non-invasive marker suspected of contributing to metastasis. Serum IL-18 may a useful biological marker as independent prognostic factor of survival. In this review we cover roles of IL-18 in immune evasion, metastasis and angiogenesis, applications for chemotherapy and prognostic or diagnostic significance.
Keywords
Interleukin-18; cancer; angiogenesis; immunotherapy; predictive marker;
Citations & Related Records
연도 인용수 순위
  • Reference
1 Volin MV, Koch AE (2011). IL-18: a mediator of inflammation and angiogenesis in rheumatoid arthritis. J Interferon Cytokine Res, 31, 745-51.   DOI
2 Wang Y, Chaudhri G, Jackson RJ, Karupiah G (2009). IL-12p40 and IL-18 play pivotal roles in orchestrating the cell-mediated immune response to a poxvirus infection. J Immunol, 183, 3324-31   DOI
3 Wei YS, Lan Y, Liu YG, et al (2007). Interleukin-18 gene promoter polymorphisms and the risk of esophageal squamous cell carcinoma. Acta Oncol, 46, 1090-6.   DOI
4 Yang Y, Qiao J, Li MZ (2010). Association of polymorphisms of interleukin-18 gene promoter region with polycystic ovary syndrome in chinese population. Reprod Biol Endocrinol, 8, 125.   DOI
5 Yao JC, Phan A, Hoff PM, et al (2008). Targeting vascular endothelial growth factor in advanced carcinoid tumor: a random assignment phase II study of depot octreotide with bevacizumab and pegylated interferon alpha-2b. J Clin Oncol, 26, 1316-23.   DOI
6 Yao L, Setsuda J, Sgadari C, Cherney B, Tosato G (2001). Interleukin-18 expression induced by Epstein-Barr virusinfected cells. J Leukoc Biol, 69, 779-84.
7 Yao L, Zhang Y, Chen K, Hu X, Xu LX (2011). Discovery of IL-18 as a novel secreted protein contributing to doxorubicin resistance by comparative secretome analysis of MCF-7 and MCF-7/Dox. PLoS One, 6, 24684.   DOI
8 Ye ZB, Ma T, Li H, Jin XL, Xu HM (2007). Expression and significance of intratumoral interleukin-12 and interleukin-18 in human gastric carcinoma. World J Gastroenterol, 13, 1747-51.   DOI
9 Yeh WL, Lu DY, Liou HC, Fu WM (2011). A forward loop between glioma and microglia: glioma-derived extracellular matrix-activated microglia secrete IL-18 to enhance the migration of glioma cells. J Cell Physiol.
10 Yoneda S, Umemura T, Katsuyama Y, et al (2011) Association of serum cytokine levels with treatment response to pegylated interferon and ribavirintherapy in genotype 1 chronic hepatitis C patients. J Infect Dis, 203, 1087-95.   DOI
11 Young-Ik Son, Ramsey MD, Robbie BM, et al (2001). Lotze Interleukin-18 (IL-18) Synergizes with IL-2 to Enhance Cytotoxicity, Interferon-g Production, and Expansion of Natural Killer Cells1. Cancer Res, 61, 884-8.
12 Zaki MH, Vogel P, Body-Malapel M, Lamkanfi M, Kanneganti TD (2010). IL-18 production downstream of the Nlrp3 inflammasome confers protection against colorectal tumor formation. J Immunol, 185, 4912-20.   DOI
13 Zhang Y, Li Y, Ma Y, et al (2011). Dual effects of interleukin-18: inhibiting hepatitis B virus replication in HepG2.2.15 cells and promoting hepatoma cells metastasis. Am J Physiol Gastrointest Liver Physiol, 301, 565-73.   DOI
14 B Zhang, K-F Wu1, Y-M Lin, et al (2004). 1 Gene transfer of pro-IL-18 and IL-1b converting enzyme cDNA induces potent antitumor effects in L1210 cells. Leukemia, 18, 817-25.   DOI
15 Alagkiozidis I, Facciabene A, Tsiatas M, et al (2011). Timedependent cytotoxic drugs selectively cooperate with IL-18 for cancer chemo-immunotherapy. J Transl Med, 25, 9-77.
16 Amin MA, Mansfield PJ, Pakozdi A, et al (2007). IL-18 induces angiogenic factors in rheumatoid arthritis synovial tissue fibroblasts via distinct signaling pathways. Arthritis Rheum, 56, 1787-97.   DOI
17 Asefi V, Mojtahedi Z, Khademi B, Naeimi S, Ghaderi A (2009). Hand neck squamous cell carcinoma is not associated with interleukin-18 promoter gene polymorphisms: a case-control study. J Laryngol Otol, 123, 444-8.   DOI
18 Badiola I, Olaso E, Crende O, Friedman SL, Vidal-Vanaclocha F (2011). Discoidin domain receptor 2 deficiency predisposes hepatic tissue to colon carcinoma metastasis. Gut.
19 Bouzgarrou N, Hassen E, Schvoerer E, et al (2008). Association of interleukin-18 polymorphisms and plasma level with the outcome of chronic HCV infection. J Med Virol, 80, 607-14.   DOI
20 Cao Q, Cai W, Niu G, He L, Chen X (2008). Multimodality imaging of IL-18--binding protein-Fc therapy of experimental lung metastasis. Clin Cancer Res, 14, 6137-45.   DOI
21 Cao R, Farnebo J, Kurimoto M, Cao Y (1999). IL-18 acts as an angiogenesis and tumor suppressor. FASEB J, 13, 2195-202.   DOI
22 Carbone A, Vizio B, Novarino A, et al (2009). IL-18 paradox in pancreatic carcinoma: elevated serum levels of free IL-18 are correlated with poor survival. J Immunother, 32, 920-31.   DOI
23 Coughlin CM, Salhany KE, Wysocka M, et al (1998). Interleukin-12 and interleukin-18 synergistically induce murine tumor regression which involves inhibition of angiogenesis. J Clin Invest, 101, 1441-52.   DOI
24 Chattergoon MA, Levine JS, Latanich R, et al (2011). High plasma interleukin-18 levels mark the acute phase of hepatitis C virus infection. J Infect Dis, 204, 1730-40.   DOI
25 Cho D, Song H, Kim YM, et al (2000). Endogenous interleukin-18 modulates immune escape of murine melanoma cells by regulating the expression of Fas ligand and reactive oxygen intermediates. Cancer Res, 60, 2703-9.
26 Cho ML, Jung YO, Moon YM, et al (2006). IL-18 induces the production of vascular endothelial growth factor (VEGF) in rheumatoid arthritis synovial fibroblasts via AP-1-dependent pathways. Immunol Lett, 103, 159-66.   DOI
27 Cui G, Yuan A, Goll R, et al (2007). Distinct changes of dendritic cell number and IL-12 mRNA level in adjacent mucosa throughout the colorectal adenoma-carcinoma sequence. Cancer Immunol Immunother, 56, 1993-2001.   DOI
28 Diakowska D, Markocka-Maczka K, Grabowski K, Lewandowski A (2006). Serum interleukin-12 and interleukin-18 levels in patients with oesophageal squamous cell carcinoma. Exp Oncol, 28, 319-22.
29 Eissa SA, Zaki SA, El-Maghraby SM, Kadry DY (2005). Importance of serum IL-18 and RANTES as markers for breast carcinoma progression. J Egypt Natl Canc Inst, 17, 51-5.
30 Elaraj DM, Weinreich DM, Varghese S, et al (2006). The role of interleukin 1 in growth and metastasis of human cancer xenografts. Clin Cancer Res, 12, 1088-96.   DOI
31 Elias AS, et al. 2009, PD-1 Induced IL10 Production by Monocytes Impairs T-cell Activation in a Reversible Fashion. Nature Medicine, 452-9.
32 Gollob JA, Mier JW, Veenstra K, et al (2000). Phase I trial of twice-weekly intravenous interleukin 12 in patients with metastatic renal cell cancer or malignant melanoma: ability to maintain IFN-gamma induction is associated with clinical response. Clin Cancer Res, 6, 1678-92.
33 Farhat K, Hassen E, Bouzgarrou N, et al (2008). Functional IL-18 promoter gene polymorphisms in Tunisian nasopharyngeal carcinoma patients. Cytokine, 43, 132-7.   DOI   ScienceOn
34 Farjadfar A, Mojtahedi Z, Ghayumi MA, et al (2009). Interleukin-18 promoter polymorphism is associated with lung cancer: a case-control study. Acta Oncol, 48, 971-6.   DOI   ScienceOn
35 Fujita K, Ewing CM, Isaacs WB, Pavlovich CP (2011). Immunomodulatory IL-18 binding protein is produced by prostate cancer cells and its levels in urine and serum correlate with tumor status. Int J Cancer, 129, 424-32.   DOI
36 Haghshenas MR, Hosseini SV, Mahmoudi M, Saberi-Firozi M, Farjadian S, Ghaderi A (2009). IL-18 serum level and IL-18 promoter gene polymorphism in Iranian patients with gastrointestinal cancers. J Gastroenterol Hepatol, 24, 1119-22.   DOI
37 Han Ming-yong, Zheng Shu, Yu Jin-ming, et al (2004). Study on interleukin-18 gene transfer into human breast cancer cells to prevent tumorigenicity. J Zhejiang Univ SCI, 5, 472-6.   DOI
38 Ingram JT, Yi JS, Zajac AJ (2011). Exhausted CD8 T cells downregulate the IL-18 receptor and become unresponsive to inflammatory cytokines and bacterial co-infections. PLoS Pathog, 7, 1002273.   DOI
39 Jablonska E, Puzewska W, Grabowska Z, Jablonski J, Talarek L (2005). VEGF, IL-18 and NO production by neutrophils and their serum levels in patients with oral cavity cancer. Cytokine, 30, 93-9.   DOI
40 Jebreel A, Mistry D, Loke D, et al (2007). Investigation of interleukin 10, 12 and 18 levels in patients with head and neck cancer. J Laryngol Otol, 121, 246-52.
41 Jung MK, Park Y, Song SB, et al (2011). Erythroid differentiation regulator 1, an interleukin 18-regulated gene, acts as a metastasis suppressor in melanoma. J Invest Dermatol, 131, 2096-104.   DOI
42 Kang JS, Bae SY, Kim HR, et al (2009). Interleukin-18 increases metastasis and immune escape of stomach cancer via the downregulation of CD70 and maintenance of CD44. Carcinogenesis, 30, 1987-96.   DOI
43 Kaser A, Novick D, Rubinstein M, et al (2002). Tilg interferon-a induces interleukin-18 binding protein in chronic hepatitis C patients. Clin Exp Immunol, 129, 332-8   DOI
44 Kei-ichi Y, Rachael C, Rebecca D, et al (2006). Kupper1 Expression of Interleukin-18 and Caspase-1in Cutaneous T-Cell Lymphoma. Clin Cancer Res, 12, 2.
45 Khalili-Azad T, Razmkhah M, Ghiam AF, et al (2009). Association of interleukin-18 gene promoter polymorphisms with breast cancer. Neoplasma, 56, 22-5.   DOI
46 Khatri A, Husaini Y, Ow K, Chapman J, Russell PJ (2009). Cytosine deaminase-uracil phosphoribosyltransferase and interleukin (IL)-12 and IL-18: a multimodal anticancer interface marked by specific modulation in serum cytokines. Clin Cancer Res, 15, 2323-34.   DOI
47 Kim J, Kim C, Kim TS, et al (2006). IL-18 enhances thrombospondin-1 production in human gastric cancer via JNK pathway. Biochem Biophys Res Commun, 344, 1284-9.   DOI
48 Kim J, Shao Y, Kim SY, et al (2008). Hypoxia-induced IL-18 increases hypoxia-inducible factor-1alpha expression through a Rac1-dependent NF-kappaB pathway. Mol Biol Cell, 19, 433-44.
49 Kim KE, Song H, Kim TS, et al (2007). IL-18 is a critical factor for vascular endothelial growth factor-enhanced migration in human gastric cancer cell lines. Oncogene, 26, 1468-76.   DOI
50 Kim KE, Song H, Hahm C, et al (2009). Expression of ADAM33 is a novel regulatory mechanism in IL-18-secreted process in gastric cancer. J Immunol, 182, 3548-55.   DOI
51 Kim YS, Cheong JY, Cho SW, et al (2009). A functional SNP of the Interleukin-18 gene is associated with the presence of hepatocellular carcinoma in hepatitis B virus-infected patients. Dig Dis Sci, 54, 2722-8.   DOI
52 Kinoshita M, Miyazaki H, Ono S, et al (2011). Enhancement of neutrophil function by interleukin-18 therapy protects burn-injured mice from methicillin-resistant Staphylococcus aureus. Infect Immun, 79, 2670-80.   DOI
53 Kuryliszyn-Moskal A, Dubicki A, Zarzycki W, Zonnenberg A, Gorska M (2011). Microvascular abnormalities in capillaroscopy correlate with higher serum IL-18 and sEselectin levels in patients with type 1 diabetes complicated by microangiopathy. Folia Histochem Cytobiol, 49, 104-10.   DOI
54 Ledee N, Petitbarat M, Rahmati M, et al (2011). New preconception immune biomarkers for clinical practice: interleukin-18, interleukin-15 and TWEAK on the endometrial side, G-CSF on the follicular side. J Reprod Immunol, 88, 118-23.   DOI
55 Li W, Kubo S, Okuda A, et al (2010). Effect of IL-18 on expansion of gammadelta T cells stimulated by zoledronate and IL-2. J Immunother, 33, 287-96.   DOI
56 Lissoni P, Brivio F, Rovelli F, et al (2000). Serum concentrations of interleukin-18 in early and advanced cancer patients: enhanced secretion in metastatic disease. J Biol Regul Homeost Agents, 14, 275-7.
57 Michael JR, John MK, Theodore FL, et al (2010). Dar4 A Dose-Escalation Study of Recombinant Human Interleukin-18 Using Two Different Schedules of Administration in Patients with Cancer. Clin Cancer Res, 14, 11.
58 Liu Y, Lin N, Huang L, Xu Q, Pang G (2007). Genetic polymorphisms of the interleukin-18 gene and risk of prostate cancer. DNA Cell Biol, 26, 613-8.   DOI
59 Majima T, Ichikura T, Chochi K, et al (2006). Exploitation of interleukin-18 by gastric cancers for their growth and evasion of host immunity. Int J Cancer, 118, 388-95.   DOI
60 Majima T, Ichikura T, Seki S, et al (2002). The influence of interleukin-10 and interleukin-18 on interferon-gamma production by peritoneal exudate cells in patients with gastric carcinoma. Anticancer Res, 22, 1193-9.
61 Mohran ZY, Ali-Eldin FA, Abdel Aal HA (2011). Serum interleukin-18: does it have a role in the diagnosis of hepatitis C virus related hepatocellular carcinoma? Arab J Gastroenterol, 12, 29-33.   DOI
62 Mojtahedi Z, Khademi B, Hashemi SB, et al (2011). Serum interleukine-6 concentration, but not interleukine-18, is associated with head and neck squamous cell carcinoma progression. Pathol Oncol Res, 17, 7-10.   DOI
63 Muller J, Feige K, Wunderlin P, et al (2011). Double-blind placebo-controlled study with interleukin-18 and interleukin-12-encoding plasmid DNA shows antitumor effect in metastatic melanoma in gray horses. J Immunother, 34, 58-64.   DOI
64 Nilkaeo A, Bhuvanath S (2006). Role of interleukin-18 in modulation of oral carcinoma cell proliferation. Mediators Inflamm, 3, 67120.
65 Nishio S, Yamada N, Ohyama H, et al (2008). Enhanced suppression of pulmonary metastasis of malignant melanoma cells by combined administration of alphagalactosylceramide and interleukin-18. Cancer Sci, 99, 113-20.
66 Page F, Galon J, Galina K, et al (2005). Wolf-Herman Fridman, and Berthold Henglein Epstein-Barr virus nuclear antigen 2 induces interleukin-18 receptor expression in B cells. Blood, 105, 1632-9.   DOI
67 Nong LG, Luo B, Zhang L, Nong HB (2009). Interleukin-18 gene promoter polymorphism and the risk of nasopharyngeal carcinoma in a Chinese population. DNA Cell Biol, 28, 507-13.   DOI   ScienceOn
68 Okamoto M, Azuma K, Hoshino T, et al (2009). Correlation of decreased survival and IL-18 in bone metastasis. Intern Med, 48, 763-73.   DOI
69 Orengo AM, Fabbi M, Miglietta L, et al (2010). Interleukin (IL)-18, a biomarker of human ovarian carcinoma, is predominantly released as biologically inactive precursor. Int J Cancer.
70 Park CC, Morel JC, Amin MA, et al (2001). Evidence of IL-18 as a novel angiogenic mediator. J Immunol, 167, 1644-53.   DOI
71 Park S, Cheon S, Cho D (2007). The dual effects of interleukin-18 in tumor progression. Cell Mol Immunol, 4, 329-35.
72 Qiao H, Sonoda KH, Ikeda Y, et al (2007). IL-18 regulates pathological intraocular neovascularization. J Leukoc Biol, 81, 1012-21.   DOI
73 Redlinger RE Jr, Mailliard RB, Lotze MT, Barksdale EM Jr (2003). Synergistic interleukin-18 and low-dose interleukin-2 promote regression of established murine neuroblastoma in vivo. J Pediatr Surg, 38, 301-7.   DOI
74 Robertson MJ, Mier JW, Logan T, et al (2006). Clinical and biological effects of recombinant humaninterleukin-18 administered by intravenous infusion to patients with advanced cancer. Clin Cancer Res, 12, 4265-73.   DOI
75 Rovina N, Hillas G, Dima E, et al (2011). VEGF and IL-18 in induced sputum of lung cancer patients. Cytokine, 54, 277-81.   DOI   ScienceOn
76 Salcedo R, Worschech A, Cardone M, et al (2010).MyD88-mediated signaling prevents development of adenocarcinomas of the colon: role of interleukin 18. J Exp Med, 207, 1625-36.   DOI
77 Sabel MS, Su G, Griffith KA, Chang AE (2010). Intratumoral delivery of encapsulated IL-12, IL-18 and TNF-alpha in a model of metastatic breast cancer. Breast Cancer Res Treat, 122, 325-36.   DOI
78 Saenz-Lopez P, Carretero R, Vazquez F, et al (2010). Impact of interleukin-18 polymorphisms-607 and -137 on clinical characteristics of renal cell carcinoma patients. Hum Immunol, 71, 309-13.   DOI
79 Salado C, Olaso E, Gallot N, et al (2011). Resveratrol prevents inflammation-dependent hepatic melanoma metastasis by inhibiting the secretion and effects of interleukin-18. J Transl, 9, 59.   DOI
80 Samsami DA, Shahriary K, Kashef MA, et al (2009). Interleukin-18 gene promoter and serum level in women with ovarian cancer. Mol Biol Rep, 36, 2393-7.   DOI
81 Setsuda J, Teruya-Feldstein J, Harris NL, et al (1999). Interleukin-18, interferon-gamma, IP-10, and Mig expression in Epstein-Barr virus-induced infectious mononucleosis and posttransplant lymphoproliferative disease. Am J Pathol, 155, 257-65.   DOI
82 Skopiński P, Rogala E, Duda-Krol B, et al (2005). Increased IL-18 content and angiogenic activity of sera from diabetic (Type 2) patients with background retinopathy. J Diabetes Complications, 19, 335-8.   DOI
83 Sobti RC, Shekari M, Tamandani DM, Malekzadeh K, Suri V (2008). Association of interleukin-18 gene promoter polymorphism on the risk of cervix carcinogenesis in north Indian population. Oncol Res, 17, 159-66.   DOI
84 Tasaki K, Yoshida Y, Maeda T, et al (2000). Protective immunity is induced in murine colon carcinoma cells by the expression of IL-12 orIL-18, which activate type 1 helper T cells. Cancer Gene Ther, 7, 247-54.   DOI
85 Song H, Kim J, Lee HK, et al (2011). Selenium inhibits migration of murine melanoma cells via down-modulation of IL-18 expression. Int Immunopharmacol.
86 Srabovic N, Mujagic Z, Mujanovic-Mustedanagic J, Muminovic Z, Cickusic E (2011). Interleukin 18 expression in the primary breast cancer tumour tissue. Med Glas Ljek komore Zenicko-doboj kantona, 8, 109-15.
87 Tangkijvanich P, Thong-Ngam D, Mahachai V, Theamboonlers A, Poovorawan Y (2007). Role of serum interleukin-18 as a prognostic factor in patients with hepatocellular carcinoma. World J Gastroenterol, 13, 4345-9.   DOI
88 Terme M, Ullrich E, Aymeric L, et al (2011). IL-18 induces PD-1-dependent immunosuppression in cancer. Cancer Res, 71, 5393-9.   DOI
89 Thong-Ngam D, Tangkijvanich P, Lerknimitr R, et al (2006). Diagnostic role of serum interleukin-18 in gastric cancer patients. World J Gastroenterol, 12, 4473-7.   DOI
90 Tsuboi K, Miyazaki T, Nakajima M, et al (2004). Serum interleukin-12 and interleukin-18 levels as a tumor marker in patients with esophageal carcinoma. Cancer Lett, 205, 207-14.   DOI
91 Tsurumi H, Kasahara S, Kanemura N, et al (2011). Serum interleukin-18 level is associated with the outcome of patients with diffuse large B-cell lymphoma treated with CHOP or R-CHOP regimens. Eur J Haematol, 87, 217-27.   DOI
92 Vairaktaris E, Serefoglou ZC, Yapijakis C, et al (2007). The interleukin-18 -607A/C polymorphism is not associated with risk for oral cancer. Anticancer Res, 27, 4011-4.